Research
Hormonal
Current anti-obesity medications primarily focus on increasing satiety and reducing appetite.
Practitioners should be aware of the current focus of obesity medications when considering treatment options.
StrongSupportsmedium confidence
Current anti-obesity medications are mostly centralized around the energy input part of the energy balance equation by increasing satiety and reducing appetite.
Why this rating
The claim is based on a clear statement regarding the focus of existing medications.
Source
Targeting the Gut in Obesity: Signals from the Inner Surface
Natalia Petersen et al. · Metabolites · 2022
DOI 10.3390/metabo12010039
reviewCited 8×
Read the paper DOI resolved against Crossref · corpus check 2026-06-10
More from this paper
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →